<DOC>
	<DOCNO>NCT03071926</DOCNO>
	<brief_summary>Metronomic PLD Patients Primary Endocrine Resistant ABC</brief_summary>
	<brief_title>Metronomic PLD Patients With Primary Endocrine Resistant ABC</brief_title>
	<detailed_description>Efficacy Safety Metronomic Pegylated Liposomal Doxorubicin Patients Primary Endocrine Resistant Advanced Breast Cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Females age 18 75 year old 2 . ECOG : 0～2 3 . Life expectancy longer 3 month 4 . Histological proven unresectable recurrent metastatic HR positive/HER2 negative breast cancer 5 . Primary endocrine resistance define : relapse first 2 year adjuvant ET , PD within first 6 month firstline ET MBC , ET 6 . At least one measurable disease accord RECIST 1.1 ( except bone metastasis ) 7 . LVEF ≥ 55 % 8 . No radiation therapy within 4 week prior enrollment 9 . Normal function major organ : Hb ≥ 90 g/L ( blood transfusion within 14 day ) ; ANC ≥1.5×109 /L；PLT ≥75×109 /L；TBIL≤1 . 5×ULN ; ALT、 AST≤ 3×ULN（ALT、 AST≤ 5×ULN hepatic metastases） ; serum Cr ≤ 1×ULN 10 . Be willing participate study , sign inform consent cooperate followup 1 . Previous accumulated equivalent dose doxorubicin ≥300mg/m2 2 . Intervals anthracyclinebased adjuvant chemotherapy ≤1 year ( time anthracyclinebased adjuvant neoadjuvant chemotherapy disease relapse ) 3 . Patients symptomatic central nervous system metastasis . Except patient stable asymptomatic brain metastasis least 8 week need glucocorticoid mannitol treatment trial least one measurable lesion outside brain . Radiotherapy brain metastasis complete least 4 week registration 4 . Pregnant lactate woman gestational age woman unable use effective contraception 5 . Treatment investigational product within 4 week study 6 . Severe cardiopulmonary insufficiency , severe hepatic renal dysfunction 7 . Severe uncontrolled infection 8 . Psychiatric drug abuse unable withdrawal mental disorder 9 . Other malignancy , except cure skin basal cell carcinoma cervical intraepithelial neoplasia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>